Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $17.00 Average Price Target from Analysts

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) has been given an average recommendation of “Hold” by the three research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and one has issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $17.00.

A number of research firms have issued reports on VRCA. Zacks Research raised Verrica Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, May 11th. Wall Street Zen downgraded Verrica Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th.

Verrica Pharmaceuticals Price Performance

VRCA opened at $5.87 on Tuesday. The firm has a market cap of $100.85 million, a P/E ratio of -5.70 and a beta of 1.54. The firm has a 50-day moving average of $6.09 and a 200 day moving average of $6.36. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.98 and a current ratio of 2.10. Verrica Pharmaceuticals has a fifty-two week low of $3.28 and a fifty-two week high of $9.82.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its earnings results on Tuesday, May 12th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.18. Verrica Pharmaceuticals had a negative return on equity of 1,077.78% and a negative net margin of 47.97%.The business had revenue of $5.02 million during the quarter, compared to the consensus estimate of $4.51 million. On average, research analysts expect that Verrica Pharmaceuticals will post -1.84 EPS for the current year.

Institutional Trading of Verrica Pharmaceuticals

Large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. purchased a new stake in Verrica Pharmaceuticals in the fourth quarter worth $155,000. HRT Financial LP purchased a new position in shares of Verrica Pharmaceuticals in the fourth quarter valued at $144,000. Beck Mack & Oliver LLC purchased a new position in shares of Verrica Pharmaceuticals in the fourth quarter valued at $100,000. Quadrature Capital Ltd purchased a new position in shares of Verrica Pharmaceuticals in the fourth quarter valued at $99,000. Finally, Man Group plc purchased a new position in shares of Verrica Pharmaceuticals in the fourth quarter valued at $94,000. 42.45% of the stock is owned by hedge funds and other institutional investors.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off?label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next?generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.